F. de Vassal

1.2k total citations · 1 hit paper
32 papers, 826 citations indexed

About

F. de Vassal is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, F. de Vassal has authored 32 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 8 papers in Genetics. Recurrent topics in F. de Vassal's work include Lymphoma Diagnosis and Treatment (8 papers), Acute Lymphoblastic Leukemia research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). F. de Vassal is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Acute Lymphoblastic Leukemia research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). F. de Vassal collaborates with scholars based in France, United States and Belgium. F. de Vassal's co-authors include L Schwarzenberg, M. Hayat, G Mathé, Jeanne Amiel, M. Schneider, Jean Schlumberger, A Cattan, C Jasmin, J. L. Misset and M Musset and has published in prestigious journals such as The Lancet, Cancer and Cancer Immunology Immunotherapy.

In The Last Decade

F. de Vassal

31 papers receiving 715 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA

1969 452 citations G Mathé, Jeanne Amiel et al. The Lancet profile →

Peers

Countries citing papers authored by F. de Vassal

Since Specialization

Citations

This map shows the geographic impact of F. de Vassal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. de Vassal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. de Vassal more than expected).

Fields of papers citing papers by F. de Vassal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. de Vassal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. de Vassal. The network helps show where F. de Vassal may publish in the future.

Co-authorship network of co-authors of F. de Vassal

This figure shows the co-authorship network connecting the top 25 collaborators of F. de Vassal. A scholar is included among the top collaborators of F. de Vassal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. de Vassal. F. de Vassal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I‐II study of aclarubicin for treatment of acute myeloid leukaemia 1987 ·European Journal Of Haematology ·D. Machover, J Gastiaburu, (unknown), Emma Goldschmidt, Manuel Benavides, J.L. Misset, F. de Vassal, Haïm Tapiero, Patricia Ribaud, L Schwarzenberg, G Mathé, (unknown), Jean‐Pierre Lotz	2
2	Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long‐term maintenance chemotherapy 1984 ·Cancer ·D. Machover, Henry Rappaport, L Schwarzenberg, J.L. Misset, Emma Goldschmidt, G Lemaigre, Thierry Dorval, F. de Vassal, Patricia Ribaud, (unknown), G Mathé	10
3	Vindesine: A New Vinca Alkaloid 1980 ·Recent results in cancer research ·M. Bayssas, J. Gouveia, F. de Vassal, J. L. Misset, L Schwarzenberg, Patricia Ribaud, M Musset, C Jasmin, M. Hayat, G Mathé	15
4	Some New Chemotherapeutic Agents and Combinations Possibly Available for New Adjuvant Therapies of Minimal Disease 1979 ·Recent results in cancer research ·G Mathé, (unknown), J. L. Misset, M. Bayssas, J. Gouveia, F. de Vassal, (unknown), Marine Gil, Patricia Ribaud, D. Machover, (unknown), D Dantchev	1
5	Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas 1979 ·Cancer Chemotherapy and Pharmacology ·M. Bayssas, J. Gouveia, Patricia Ribaud, M Musset, F. de Vassal, J. L. Pico, Luciana De Luca, J. L. Misset, D. Machover, D Belpomme, L Schwarzenberg, C Jasmin, M. Hayat, G Mathé	22
6	Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine. 1978 ·PubMed ·G Mathé, J. L. Misset, F. de Vassal, J. Gouveia, M. Hayat, D. Machover, D Belpomme, J. L. Pico, L Schwarzenberg, Patricia Ribaud, M Musset, C Jasmin, Luciana De Luca	47
7	Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: Distinction of two groups of patients according to predictable prognosis 1978 ·Medical and Pediatric Oncology ·G Mathé, F. de Vassal, L Schwarzenberg, Miguel Delgado‐Rodríguez, Roy S. Weiner, Marine Gil, (unknown), D Belpomme, P Pouillart, D. Machover, J. L. Misset, J. L. Pico, C Jasmin, M. Hayat, M. Schneider, A Cattan, Jeanne Amiel, M Musset, C. Rosenfeld, Patricia Ribaud	9
8	Preliminary Results of Chemoradiotherapy Followed (or Not) by Active Immunotherapy of Stage III and IV Lymphosarcoma and Reticulosarcoma: Correlation of the Results with WHO Categorization 1978 ·Recent results in cancer research ·J. L. Misset, G Mathé, M Tubiana, Bernard Caillou, F. de Vassal, P Pouillart, Marine Gil, (unknown), M. Hayat, L Schwarzenberg, C Jasmin, Miguel Delgado‐Rodríguez, D. Machover, Patricia Ribaud, M Musset	1
9	1975 current results of the first 100 cytologically typed acute lymphoid leukemia submitted to BCG active immunotherapy 1976 ·Cancer Immunology Immunotherapy ·G Mathé, F. de Vassal, Miguel Delgado‐Rodríguez, P Pouillart, D Belpomme, (unknown), L Schwarzenberg, Jeanne Amiel, M. Schneider, A Cattan, M Musset, J. L. Misset, C Jasmin	14
10	IMMUNOTHERAPY FOR ACUTE LYMPHOID LEUKÆMIA 1976 ·The Lancet ·G Mathé, L Schwarzenberg, F. de Vassal, Miguel Delgado‐Rodríguez	6
11	Remission Induction in Acute Lymphoid and Acute Myeloid LeukÆmias 1976 ·The Lancet ·G Mathé, J. L. Misset, P Pouillart, (unknown), F. de Vassal, C Jasmin, Mario Delgado, D Belpomme, L Schwarzenberg, M Musset	2
12	Immunothérapie active des leucémies aiguës et des lymphosarcomes leucémiques. Bilar de 10 ans-Etude de 200 cas 1975 ·La Nouvelle presse médicale ·(unknown), Jeanne Amiel, L Schwarzenberg, (unknown), P Pouillart, (unknown), A Cattan, C Jasmin, D Belpomme, Jean Schlumberger, F. de Vassal, M Musset, J.L. Misset	3
13	Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas 1974 ·Cancer ·G Mathé, L Schwarzenberg, P Pouillart, R. K. Oldham, Roy S. Weiner, C Jasmin, C. Rosenfeld, M. Hayat, J. L. Misset, M Musset, M. Schneider, Jeanne Amiel, F. de Vassal	89
14	Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase 1973 ·BMJ ·L Schwarzenberg, G Mathé, P Pouillart, Roy S. Weiner, (unknown), (unknown), M. Schneider, F. de Vassal, M. Hayat, Jeanne Amiel, Jean Schlumberger, C Jasmin, (unknown)	21
15	Remission Induction with Poly IC in Patients with Acute Lymphoblastic Leukemia (Preliminary Results) 1971 ·PubMed ·G Mathé, Jeanne Amiel, L Schwarzenberg, M. Schneider, M. Hayat, F. de Vassal, C Jasmin, C. Rosenfeld, (unknown), J Choay	7
16	Pathogen-free isolation unit — Three years' experience 1969 ·BMJ ·M. Schneider, L Schwarzenberg, Jeanne Amiel, A Cattan, Jean Schlumberger, M. Hayat, F. de Vassal, (unknown), (unknown), G Mathé	13
17	[A new combination of methotrexate and folinic acid for cancer treatment (acute leukemia and solid tumors)]. 1969 ·PubMed ·L Schwarzenberg, G Mathé, M. Hayat, F. de Vassal, Jeanne Amiel, A Cattan, Martina Schneider, Jean Schlumberger, C. Rosenfeld, C Jasmin, (unknown)	10
18	ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA breakdown → 1969 ·The Lancet ·G Mathé, Jeanne Amiel, L Schwarzenberg, M. Schneider, A Cattan, Jean Schlumberger, M. Hayat, F. de Vassal	452
19	Greffe de moelle osseuse allogénique chez l'hormme provée par six marqueurs antigéniques après conditionnnement du receveur et du donneur par le sérum antilymphocytaire. 1968 ·G Mathé, Jeanne Amiel, L Schwarzenberg, Matthias Schneider, (unknown), Jean Schlumberger, (unknown), F. de Vassal, C Jasmin, (unknown), (unknown), (unknown)	3
20	NEW ANTIGENS IN HUMAN LEUKÆMIC CELLS, AND ANTIBODY IN THE SERUM OF LEUKÆMIC PATIENTS 1967 ·The Lancet ·J F Doré, (unknown), (unknown), F. de Vassal, R Motta, Ivo Hřsak, G Seman, G Mathé	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact